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Author's View
Many long-standing problems in sci-
ence, medicine, or engineering are solved 
when new approaches become possible 
and are ardently applied. After many years 
of best efforts and countless dollars, but 
unmet expectations, cancer vaccines have 
become a long-standing problem. We and 
others have proposed that neoantigens – 
a newly available class of immunogens 
based on the personal, exquisitely tumor-
specific mutations found uniquely in each 
tumor – may be the paradigm shift needed 
for cancer vaccines (Fig. 1).1,2
Developing novel approaches requires 
commitment to a path without precedent 
and engaging in activities that system-
atically contribute to maintaining the 
momentum needed for change - capturing 
information to support the concept, rais-
ing, but not being paralyzed by, potential 
challenges, and identifying current short-
comings in knowledge or capabilities. In 
the following three sections we: (1) iden-
tify new results that continue to encourage 
the development of neoantigen vaccines; 
(2) highlight potential shortfalls of a neo-
antigen approach, and (3) point out areas 
where we challenge immunologists, bio-
chemists and bioinformaticians to expand 
our basic knowledge and capabilities to 
help realize this novel opportunity for 
treatment of such a dreaded disease.
New Information
Data supporting the critical role of 
neoantigens in immune control has con-
tinued to build.
•  Neoantigens  represent  dominant  tar-
gets in tumor-infiltrating lymphocyte 
(TIL) populations in patients ben-
efiting from adoptive therapy and a 
neoantigen-specific population was 
sufficient to induce tumor regression 
in mouse and man3-6 (T. Schumacher, 
personal communication).
• The widespread detection of spontane-
ously occurring neoantigen-specific T 
cells5,7,8 demonstrates that processing 
and presentation of multiple neoan-
tigens does occur, despite the current 
insensitivity of biochemical detection 
on tumors.
•  Checkpoint  blockade  therapy  has 
revealed new and amplified neo-
antigen-specific responses which, 
in the mouse, are central to dis-
ease control8 (R. Schreiber, personal 
communication).
•  Building  on  our  previous  results  that 
T cells in autologous leukemia cell 
vaccinated patients recognize tumor-
specific antigens,9 we have identified 
a neoantigen as one of these targets10.
• Our comprehensive literature analysis of 
multiple spontaneous human neoan-
tigen responses showed that all were 
predictable using available algorithms 
for MHC binding and provided guid-
ance for epitope selection7.
• A retrospective meta-analysis of six tumor 
types showed that overall survival was 
improved in patients predicted to have 
at least one immunogenic neoantigen 
epitope.11
Two clinical trials have now been ini-
tiated to directly test the concept of a 
neoantigen  vaccine  (NCT01970358  and 
NCT02035956).
Valid Questions
Guilty until proven innocent is a valid 
scientific philosophy and so multiple ques-
tions challenge the viability of a neoanti-
gen vaccine.
• By the time cancer is detected, would a 
vaccine approach have lost its chance 
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due to local and systemic immune sup-
pression? Paradoxically, the success 
of checkpoint blockade in producing 
durable remission in a significant sub-
set of patients has both validated the 
physiological importance of immune 
suppression but also validated that 
pharmacological intervention can 
shift that delicate balance toward 
tumor  control.  Correspondingly,  we 
posit that the spontaneous immune 
reaction to a slowly growing and 
evolving tumor is likely sub-optimal, 
especially in the absence of appropri-
ate ‘danger’ signals, and that a multi-
epitope, neoantigen-based vaccine 
delivered with a powerful adjuvant has 
the ability to productively impact the 
clinical response.
•  Is a multi-epitope, personalized vaccine 
too impractical to manufacture for 
widespread use? We reject this barrier 
to innovation. Interwoven key con-
cerns frequently raised include cost, 
timing, and good manufacturing 
practice (GMP). Ultimately, engineer-
ing, focused technology development 
and logistics will solve these problems 
if clinical benefit is demonstrated. The 
cost of sequencing continues to fall and 
a properly scaled and designed process 
along with a streamlined approach to 
product assays can maintain manufac-
turing time and cost within acceptable 
limits. Finally, regulatory authorities 
have always responded to exciting new 
therapeutic opportunities with coop-
eration and adaptability.
•  Will genetic heterogeneity within the 
tumor always result in cells resistant 
to immune attack? Tumor evolution 
is driven by multiple independent 
pressures, including immune pres-
sure, and results in genetic variation 
over time and space. Heterogeneity 
is thus a primary rationale for utiliz-
ing multiple independent epitopes in 
a vaccine, reducing the possibility of 
immune escape due to downregula-
tion of a single antigen.
A Call to Arms
A silver lining, if there can be one, of the 
failure of past cancer vaccine approaches 
has been the continual improvement to 
vaccine strategies. We further encourage 
work in the following areas to strengthen 
our understanding of antigen processing, 
presentation and detection and thus maxi-
mize the potential of this novel immuno-
gen class:
•  Discovering  the  rules  for  proteasomal 
processing in professional APCs and 
tumor cells to provide in silico fil-
ters  to  complement  MHC  binding 
predictions.
•  Developing  the  capability  to  predict 
which mutated peptides are presented 
by  MHC  class  II  to  CD4+ T cells. 
CD4+ T cell help against tumor-
expressed neoantigens may be impor-
tant for stimulating local responses 
within the tumor.
•  Developing  rapid  assays  to  measure 
candidate neoantigen processing and 
presentation  by  APC  and  the  sub-
sequent activation of T cells ex vivo. 
Such assays will help to refine rules of 
processing and may provide real-time 
guidance in epitope selection.
Conclusion
The recent failure of the MAGE-A3 
vaccine to meet the first two primary 
endpoints in its non-small cell lung can-
cer trial sent chills through an already 
stymied set of cancer vaccine proponents. 
The old adage ‘If wishes were horses, then 
beggars would ride’ is a sobering reminder 
that to move forward we need results. We 
anticipate that neoantigen vaccination 
will provide such results by fostering anti-
cancer immunity.
Figure 1. the neoantigen vaccine immunotherapeutic concept. Cancer cell genomes are now 
known to contain many mutations, some of which create amino acid changes in the encoded pro-
teins. some of these modified proteins will be partially degraded by the normal cellular re-cycling 
machinery, creating short 8 to 12 amino acid peptides, and some of these peptides will bind to one 
of the class i MhC molecules of the individual. Peptide binding to MhC is a critical gateway to both 
the initiation of a t-cell immune response by the antigen presenting cell (APC), and to the detec-
tion and elimination of tumor cells presenting the particular peptide by the stimulated cytotoxic 
t lymphocyte (CtL). the attraction of neoantigens as cancer targets for the immune system results 
from the structural and geographical features of the mutation. Central tolerance is known to purge 
the vast developing t-cell population in the thymus of high avidity t-cell receptors (tCrs) that rec-
ognize MhC complexes with native peptides (‘self’). in contrast, high avidity t cells are not cen-
trally deleted against mutated peptide/MhC complexes (like viral antigens) because the mutated 
antigens are not present in thymus during t-cell development. these high avidity cytotoxic t cells 
can be selectively amplified and stimulated to attack and kill cells that present mutated peptides. 
since neoantigen peptides are only found in tumor cells, the CtLs should show exquisite specific-
ity, reducing the opportunity for autoimmune disease. Desired improvements in the process are 
shown in the box in the upper right.©
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